Altimmune, Inc.
ALT
$4.07
$0.071.75%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.00K | 5.00K | 5.00K | 5.00K | 5.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.00K | 5.00K | 5.00K | 5.00K | 5.00K |
| Cost of Revenue | 17.24M | 15.83M | 19.78M | 19.80M | 21.16M |
| Gross Profit | -17.23M | -15.82M | -19.78M | -19.80M | -21.15M |
| SG&A Expenses | 5.69M | 5.99M | 5.09M | 4.97M | 5.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.93M | 21.82M | 24.87M | 24.77M | 26.75M |
| Operating Income | -22.92M | -21.82M | -24.87M | -24.77M | -26.75M |
| Income Before Tax | -22.15M | -20.26M | -23.18M | -22.85M | -24.64M |
| Income Tax Expenses | -- | -681.00K | -- | -- | -- |
| Earnings from Continuing Operations | -22.15M | -19.58M | -23.18M | -22.85M | -24.64M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.15M | -19.58M | -23.18M | -22.85M | -24.64M |
| EBIT | -22.92M | -21.82M | -24.87M | -24.77M | -26.75M |
| EBITDA | -22.89M | -21.79M | -24.83M | -24.73M | -26.68M |
| EPS Basic | -0.27 | -0.26 | -0.33 | -0.32 | -0.35 |
| Normalized Basic EPS | -0.17 | -0.17 | -0.20 | -0.20 | -0.22 |
| EPS Diluted | -0.27 | -0.26 | -0.33 | -0.32 | -0.35 |
| Normalized Diluted EPS | -0.17 | -0.17 | -0.20 | -0.20 | -0.22 |
| Average Basic Shares Outstanding | 81.48M | 75.55M | 71.26M | 71.08M | 70.92M |
| Average Diluted Shares Outstanding | 81.48M | 75.55M | 71.26M | 71.08M | 70.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |